PPAR gamma signaling and metabolism: the good, the bad and the future

Cited 917 time in webofscience Cited 0 time in scopus
  • Hit : 456
  • Download : 0
Thiazolidinediones (TZDs) are potent insulin sensitizers that act through the nuclear receptor peroxisome proliferator-activated receptor-gamma (PPAR gamma) and are highly effective oral medications for type 2 diabetes. However, their unique benefits are shadowed by the risk for fluid retention, weight gain, bone loss and congestive heart failure. This raises the question as to whether it is possible to build a safer generation of PPAR gamma-specific drugs that evoke fewer side effects while preserving insulin-sensitizing potential. Recent studies that have supported the continuing physiologic and therapeutic relevance of the PPAR gamma pathway also provide opportunities to develop newer classes of molecules that reduce or eliminate adverse effects. This review highlights key advances in understanding PPAR gamma signaling in energy homeostasis and metabolic disease and also provides new explanations for adverse events linked to TZD-based therapy.
Publisher
NATURE PUBLISHING GROUP
Issue Date
2013-05
Language
English
Article Type
Review
Citation

NATURE MEDICINE, v.19, no.5, pp.557 - 566

ISSN
1078-8956
DOI
10.1038/nm.3159
URI
http://hdl.handle.net/10203/198268
Appears in Collection
MSE-Journal Papers(저널논문)
Files in This Item
There are no files associated with this item.
This item is cited by other documents in WoS
⊙ Detail Information in WoSⓡ Click to see webofscience_button
⊙ Cited 917 items in WoS Click to see citing articles in records_button

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0